References of "Nitsch, J"
     in
Bookmark and Share    
Peer Reviewed
See detail[Increased atrial natriuretic peptide in essential hypertension--relation to right atrial pressure behavior].
Neyses, Ludwig UL; Nitsch, J.; Tuttenberg, H. P. et al

in Klinische Wochenschrift (1989), 67(15), 756-61

The role of atrial natriuretic peptide (ANP) in the pathogenesis of essential hypertension has not yet entirely been clarified. We investigated whether the increase of ANP in essential hypertension may be ... [more ▼]

The role of atrial natriuretic peptide (ANP) in the pathogenesis of essential hypertension has not yet entirely been clarified. We investigated whether the increase of ANP in essential hypertension may be explained by elevated right atrial pressures and/or a different relationship between right atrial pressures and ANP secretion. Patients with stable essential hypertension undergoing right and left heart catheterization because of suspected coronary heart disease had significantly higher ANP levels than normotensives: 58.7 +/- 6.7 pg/ml in hypertensives versus 42.0 +/- 4.1 pg/ml in normotensives (p less than 0.01). Matching hypertensives with normotensives at identical levels of left ventricular enddiastolic pressure revealed significantly higher mean pulmonary artery pressures in hypertensives. Right atrial diastolic pressure (v-wave) after matching for LVEDP was 4.8 +/- 0.5 mm Hg in hypertensives and 3.1 +/- 0.2 mm Hg in normotensives (p less than 0.05). In addition, at any given mean right atrial pressure hypertensives showed higher ANP levels than normotensives. These results demonstrate that hypertensives exhibit raised pressures in the pulmonary artery independent of left ventricular pressure load. The elevation in right atrial pressures and the steeper relationship between these pressures and ANP are a suitable explanation for raised ANP levels in hypertension. ANP in essential hypertension may represent a counterregulation against elevated pulmonary resistance. [less ▲]

Detailed reference viewed: 47 (0 UL)
Peer Reviewed
See detail[Elevated levels of atrial natriuretic peptide and plasma catecholamines in arterial hypertension--indications for an interaction].
Neyses, Ludwig UL; Nitsch, J.; Biegel, T. et al

in Zeitschrift fur Kardiologie (1988), 77(7), 407-12

In this study plasma levels of atrial natriuretic peptide and of the catecholamines epinephrine and norepinephrine were investigated in hypertensive patients (HT) (n = 30). 22 normotensive patients (NT ... [more ▼]

In this study plasma levels of atrial natriuretic peptide and of the catecholamines epinephrine and norepinephrine were investigated in hypertensive patients (HT) (n = 30). 22 normotensive patients (NT) served as controls. Hypertensives showed an elevated ANP-level in comparison with controls (46.8 +/- 3.3 vs. 36.8 +/- 3.3 pg/ml, M +/- SEM, p less than 0.01). When patients with myocardial infarction or with reduced ejection fraction were excluded, the same relation was demonstrated (49.3 +/- 3.2 vs. 33.6 +/- 2.0 pg/ml, p less than 0.01). Plasma norepinephrine was 230.8 +/- 52.3 pg/ml in HT compared with 138.0 +/- 19.6 pg/ml in NT (p less than 0.05). Epinephrine was 70.8 +/- 10.5 vs. 54.8 +/- 9.7 pg/ml in HT and NT. To exclude an increased left ventricular enddiastolic - and hence left atrial - pressure as the cause for the elevation of ANP and norepinephrine, HT and NT were matched for the same levels of enddiastolic pressure (LVEDP) (n = 18). For each level of LVEDP ANP was higher in HT than in NT (p less than 0.01). The same held true for norepinephrine (p less than 0.05) and to a lesser extent for epinephrine (p = 0.09). Our results demonstrate that patients with essential hypertension exhibit markedly elevated levels for ANP and catecholamines which is not due to myocardial failure. We propose that the increased secretion of the vasodilatory hormone ANP serves as counterregulation against the vasoconstrictor norepinephrine. The endocrine function of the heart may play a pivotal role in the modulation of sympathetic activity. [less ▲]

Detailed reference viewed: 32 (0 UL)
Peer Reviewed
See detail[Concentrations of amiodarone and flecainide in plasma and saliva--indications for the active transport of flecainide].
Nitsch, J.; Kohler, U.; Neyses, Ludwig UL et al

in Zeitschrift fur Kardiologie (1988), 77(2), 99-102

Only the free protein-unbound drug concentration in plasma is pharmacologically active. The concentration of some drugs in saliva is equal to the free drug level. We compared concentrations (in plasma ... [more ▼]

Only the free protein-unbound drug concentration in plasma is pharmacologically active. The concentration of some drugs in saliva is equal to the free drug level. We compared concentrations (in plasma before, 30 and 60 min after the morning dose, in saliva before, 30, 60, 90 and 120 min after the morning dose) of amiodarone (n = 8, 2 x 200 mg orally per day) and flecainide (n = 16, 2 x 100 mg) administered as chronic antiarrhythmic treatment. Drug levels were measured by "high performance liquid chromatography". Results: Just prior to the first morning dose, amiodarone concentrations in plasma were 1.0-2.9 (2.0 +/- 0.6) micrograms/ml, in saliva 0.02-0.25 micrograms/ml; flecainide in plasma 80-560 (316 +/- 163) ng/ml, in saliva 630-3700 (1749 +/- 963) ng/ml. After the morning dose we found maximal flecainide plasma levels of 462 +/- 203 and saliva levels of 3218 +/- 2857 ng/ml. The highest flecainide concentrations in the saliva (13,400 and 11,300 ng/ml) were found in two patients 30 and 60 min after the morning dose. Flecainide, but not amiodarone, is excreted actively in the saliva, probably indicating an enteroenteric circulation. This should be considered to reduce life-threatening flecainide intoxications by gastric and intestinal lavage and suction. The concentration of flecainide in the saliva does not represent the non-protein-bound free drug level in the plasma. [less ▲]

Detailed reference viewed: 44 (0 UL)
Peer Reviewed
See detail[Diagnostic and prognostic value of plasma ANP determination after myocardial infarction].
Neyses, Ludwig UL; Biegel, H.; Heinrichs, S. et al

in Zeitschrift fur Kardiologie (1988), 77 Suppl 2

In the present study the prognostic value of ANP measurement was investigated in 52 patients undergoing coronary angiography. 22 normotensive and 30 hypertensive subjects were included. A significant ... [more ▼]

In the present study the prognostic value of ANP measurement was investigated in 52 patients undergoing coronary angiography. 22 normotensive and 30 hypertensive subjects were included. A significant inverse correlation between left ventricular ejection fraction (EF) and plasma ANP was found in normotensives, but not in hypertensives. In patients with chronic myocardial infarction, there was no difference in ANP levels compared to patients without infarction in either group, provided that EF was normal. However, hypertensives showed a 35% increase in ANP compared to normotensives. This was true for subjects with and without myocardial infarction. These results show that in normotensives ANP levels have a prognostic value on a statistical rather than an individual basis. This does not apply to hypertensives, whose ANP level is increased by factors other than impaired ejection fraction. [less ▲]

Detailed reference viewed: 27 (0 UL)
Peer Reviewed
See detailDiagnostische und prognostische Bedeutung der Plasma-ANP-Messung nach Myokardinfarkt
Neyses, Ludwig UL; Biegel, T; Heinrichs, S et al

in Plasmabestimmung des atrialen natriuretischen Peptids (1988)

Detailed reference viewed: 29 (0 UL)
Peer Reviewed
See detail[Elevated plasma flecainide concentrations in heart failure].
Nitsch, J.; Neyses, Ludwig UL; Kohler, U. et al

in Deutsche medizinische Wochenschrift (1946) (1987), 112(44), 1698-700

In 42 patients with heart failure who were on long-term treatment with flecainide (2 X 100 mg daily by mouth) plasma concentration of flecainide was measured before the morning dose and compared with the ... [more ▼]

In 42 patients with heart failure who were on long-term treatment with flecainide (2 X 100 mg daily by mouth) plasma concentration of flecainide was measured before the morning dose and compared with the clinical grade of heart failure or left ventricular ejection fraction (in the levo-angiogram). Mean plasma flecainide concentration was 415 +/- 244 ng/ml (110-1035 ng/ml), mean ejection fraction 55 +/- 17.7% (24-84%) (r = -0.60). In seven patients with plasma concentrations over 700 ng/ml (870 +/- 150 ng/ml) in clinical grade III or IV, ejection fractions were 24, 25, 25, 30, 33, 37 and 44%, respectively. In two patients (ejection fraction of 24 and 25%, respectively) the morning plasma concentration was around 1000 ng/ml. The results point to possible high plasma flecainide concentrations--at times in the toxic range--in patients who are in heart failure. In patients with marked reduction in left ventricular pumping function who are on long-term flecainide treatment, a reduction in dosage or monitoring of plasma flecainide concentration is indicated. [less ▲]

Detailed reference viewed: 29 (0 UL)
Peer Reviewed
See detailInhibition of flecainide absorption by activated charcoal.
Nitsch, J.; Kohler, U.; Neyses, Ludwig UL et al

in The American journal of cardiology (1987), 60(8), 753

Detailed reference viewed: 52 (0 UL)
Peer Reviewed
See detail[Resuscitation of a 36-year-old patient with a short PQ time and a history of Hodgkin's disease].
Neyses, Ludwig UL; Nitsch, J.; Manz, M. et al

in Der Internist (1987), 28(3), 196-9

Detailed reference viewed: 28 (0 UL)
Peer Reviewed
See detailEinfluss von oraler Volumenbelastung, Herzfrequenz und Reserpin auf die Sekretion von atrialem natriuretischen Peptid beim Menschen
Neyses, Ludwig UL; Nitsch, J; Heinrichs, S et al

in Kreye, V; Bussmann, W (Eds.) Atriales natriurestisches Peptid und das kardiovaskulaere System (1987)

Detailed reference viewed: 34 (0 UL)